Secarna Pharmaceuticals
Alexander Gebauer has a diverse work experience in the pharmaceutical industry. Alexander is currently the CEO of Secarna Pharmaceuticals since December 2020. Prior to that, they co-founded and served as the Executive Chairman of Galimedix Inc. starting from June 2018. Alexander also held the position of Chairman of the Board of Directors at Omeicos Ophthalmics Inc. from March 2018 to November 2020. Alexander has also served as the Managing Director of OMEICOS Therapeutics GmbH from December 2017 to November 2020. Alexander was a member of the Board of Directors at Vaccentis AG from July 2017 to July 2019. Alexander gained experience in research and development roles at SUN PHARMA as the President and Head of R&D from March 2015 to April 2016, and as the President of Ranbaxy Laboratories Ltd. from July 2014 to March 2015. Alexander has also held various positions at Merz Pharmaceuticals, including CSO and Head Global R&D from July 2006 to June 2014, and VP of Global Clinical R&D from May 2005 to June 2006. Prior to that, they worked as the VP of Global Project Direction at sanofi-aventis and as the Coordinator for LO (early development) at Aventis.
Alexander Gebauer obtained their Doctor of Medicine (MD) and PhD degrees from Johannes Gutenberg University Mainz from 1982 to 1988, specializing in the field of Medizin. Following this, they pursued a Bachelor of Applied Science (BASc) degree in Informatics at CBI, Wiesbaden, from 1988 to 1989.
This person is not in any teams
This person is not in any offices
Secarna Pharmaceuticals
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.